Quantcast
Last updated on April 23, 2014 at 16:13 EDT

Latest Oncologists Stories

2013-05-14 16:27:23

Data from Pipeline Molecules Targeting Key Cancer Pathways to be Presented INDIANAPOLIS, May 14, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will present data from key molecules that make up its clinical oncology pipeline during the 49(th) Annual Meeting of the American Society of Clinical Oncology (ASCO) held in Chicago, Ill. from May 31 - June 4, 2013. Lilly Oncology's pipeline is one of the most robust in the industry, with more than 20 molecules in early- and...

2013-05-11 23:02:33

The Bladder Cancer Advocacy Network (BCAN) has granted $300,000 to three exceptional up and coming researchers through its Young Investigator Awards program. Bethesda, MD (PRWEB) May 11, 2013 Just as National Cancer Research month begins, the Bladder Cancer Advocacy Network (BCAN) has announced the recipients of its Young Investigator Awards. BCAN´s Scientific Review Group, chaired by Matt Milowsky, MD at the University of North Carolina´s Lineberger Comprehensive Cancer Center,...

2013-05-07 12:30:39

A Therapy as Efficacious as FOLFIRINOX, but Better Tolerated, Will Quickly Become the New Standard of Care in Pancreatic Cancer, According to a New Report from Decision Resources BURLINGTON, Mass., May 7, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the pancreatic cancer therapy market will nearly double to $1.3 billion in 2022, owing to the launch and rapid uptake of three...

2013-05-03 16:22:32

SAN DIEGO, May 3, 2013 /PRNewswire-USNewswire/ -- Today, the American Urological Association (AUA) released a new Guideline on the Early Detection of Prostate Cancer, which addresses prostate cancer early detection for the purpose of reducing prostate cancer mortality. The guideline was developed through a rigorous, systematic review of published literature (including data extraction and analysis), and updates the AUA's Best Practice Statement on Prostate-Specific Antigen (PSA),...

2013-05-03 08:25:34

New app gives urologists the ability to share three-dimensional models of vital organs with patients for more complete, in-depth consultations SAN DIEGO and VANCOUVER, British Columbia, May 3, 2013 /PRNewswire/ -- GenomeDx Biosciences today announced the launch of UroSketch 3D(TM), an application available in Apple's App Store and designed specifically for the iPad. The app, which provides a three-dimensional model of the prostate, bladder and surrounding organs for use by physicians...

2013-05-01 08:29:39

Pancreatic Cancer Becomes the Fourth Tumor Type Evaluated as Part of the OGX-427 ORCA(TM) Program, In Addition to Bladder, Lung and Prostate Cancers BOTHELL, Wash. and VANCOUVER, British Columbia, May 1, 2013 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced plans for the initiation of the Rainier(TM) trial, an investigator-sponsored, randomized, placebo-controlled Phase 2 trial evaluating OGX-427 in combination with ABRAXANE(®) (paclitaxel...

2013-04-30 12:27:08

Industry Veteran to Lead Metamark Genetics in Commercialization of Novel Prognostic Tests for Prostate and Other Cancers CAMBRIDGE, Mass., April 30, 2013 /PRNewswire/ -- Metamark Genetics, Inc., a leader in the discovery of novel molecular prognostic and diagnostic tests for cancer, today announced that industry veteran Shawn M. Marcell has been named the company's new president and chief executive officer. Mr. Marcell succeeds interim executive Michael Kauffman, M.D., who will...

2013-04-30 08:34:34

The OGX-427 ORCA(TM) Program Continues to Expand with Patient Enrollment Now Open for Second Phase 2 Trial of OGX-427 in Advanced Bladder Cancer BOTHELL, Wash. and VANCOUVER, British Columbia, April 30, 2013 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced initiation of the Borealis-2(TM) clinical trial, an investigator-sponsored, randomized Phase 2 trial evaluating OGX-427 in combination with docetaxel in patients with advanced or metastatic bladder...

2013-04-29 08:27:42

Additional validation data of Decipher(TM) prostate cancer test to be presented at AUA 2013 SAN DIEGO, April 29, 2013 /PRNewswire/ -- GenomeDx Biosciences announced today that it has expanded an existing research agreement with the Mayo Clinic. The expanded agreement includes exclusive license to certain Mayo developed intellectual property along with exclusivity covering co-developed intellectual property. The agreement also includes continued access to the clinical data...

2013-04-23 08:34:12

SEATTLE, April 23, 2013 /PRNewswire/ -- VentiRx Pharmaceuticals, Inc. today announced the appointment of James Kyle Bryan, M.D. as Chief Medical Officer. A hematologist and medical oncologist, Dr. Bryan brings more than 20 years of oncology drug discovery and development experience in the pharmaceutical and biotechnology industry to VentiRx. This includes extensive operational and strategic leadership work in his previous roles as Vice President of Global Product Development at PPD,...